期刊
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
卷 1876, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.bbcan.2021.188577
关键词
Platinum; Lung cancer; Therapy; Chemoresistance
资金
- National Natural Science Foundation of China [82074069]
Platinum resistance is a challenge in lung cancer treatment, and understanding its molecular mechanisms, identifying predictive markers, and developing more effective and less toxic agents are crucial. Addressing this issue could lead to the development of improved treatment for refractory lung cancer in the future.
Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents in clinical use both of lung cancer in mono-and combination therapies. However, platinum resistance limits its clinical application. It is necessary to understand the molecular mechanism of platinum resistance, identify predictive markers, and develop newer, more effective and less toxic agents to treat platinum resistance in lung cancer. Here, it summarizes the main molecular mechanisms associated with platinum resistance in lung cancer and the development of new approaches to tackle this clinically relevant problem. Moreover, it could lead to the development of more effective treatment for refractory lung cancer in future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据